|
Gene: PCDHB2 |
Gene summary for PCDHB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PCDHB2 | Gene ID | 56133 |
Gene name | protocadherin beta 2 | |
Gene Alias | PCDH-BETA2 | |
Cytomap | 5q31.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q4KMG6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56133 | PCDHB2 | male-WTA | Human | Thyroid | PTC | 4.82e-02 | 4.69e-02 | 0.1037 |
56133 | PCDHB2 | PTC06 | Human | Thyroid | PTC | 1.69e-04 | 1.69e-01 | 0.2057 |
56133 | PCDHB2 | PTC07 | Human | Thyroid | PTC | 1.12e-09 | 1.73e-01 | 0.2044 |
56133 | PCDHB2 | ATC09 | Human | Thyroid | ATC | 2.26e-06 | 2.24e-01 | 0.2871 |
56133 | PCDHB2 | ATC11 | Human | Thyroid | ATC | 7.49e-03 | 3.98e-01 | 0.3386 |
56133 | PCDHB2 | ATC1 | Human | Thyroid | ATC | 1.52e-06 | 2.46e-01 | 0.2878 |
56133 | PCDHB2 | ATC2 | Human | Thyroid | ATC | 9.94e-09 | 7.41e-01 | 0.34 |
56133 | PCDHB2 | ATC3 | Human | Thyroid | ATC | 6.48e-06 | 3.93e-01 | 0.338 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
GO:003432924 | Thyroid | ATC | cell junction assembly | 187/6293 | 420/18723 | 1.71e-06 | 2.08e-05 | 187 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCDHB2 | insertion | Nonsense_Mutation | novel | c.984_985insAGCCTGAGATCAGGTTAACCCTCACAGCG | p.Leu329SerfsTer6 | p.L329Sfs*6 | Q9Y5E7 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
PCDHB2 | SNV | Missense_Mutation | rs139329842 | c.93G>T | p.Gln31His | p.Q31H | Q9Y5E7 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.516) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PCDHB2 | SNV | Missense_Mutation | c.1384N>A | p.Val462Ile | p.V462I | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.15) | benign(0.251) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.2113T>C | p.Phe705Leu | p.F705L | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.46) | benign(0) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
PCDHB2 | SNV | Missense_Mutation | novel | c.299N>A | p.Pro100His | p.P100H | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.13) | benign(0.007) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
PCDHB2 | SNV | Missense_Mutation | novel | c.721N>A | p.Val241Ile | p.V241I | Q9Y5E7 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
PCDHB2 | SNV | Missense_Mutation | novel | c.1348G>A | p.Ala450Thr | p.A450T | Q9Y5E7 | protein_coding | deleterious_low_confidence(0.02) | benign(0.187) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PCDHB2 | SNV | Missense_Mutation | novel | c.1880G>A | p.Arg627His | p.R627H | Q9Y5E7 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.563) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PCDHB2 | SNV | Missense_Mutation | novel | c.2183N>T | p.Ser728Leu | p.S728L | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.11) | benign(0.009) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PCDHB2 | SNV | Missense_Mutation | c.2356N>A | p.Glu786Lys | p.E786K | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.17) | benign(0.007) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |